EA029690B1 - Композиция для контроля тошноты и рвоты - Google Patents

Композиция для контроля тошноты и рвоты Download PDF

Info

Publication number
EA029690B1
EA029690B1 EA201690149A EA201690149A EA029690B1 EA 029690 B1 EA029690 B1 EA 029690B1 EA 201690149 A EA201690149 A EA 201690149A EA 201690149 A EA201690149 A EA 201690149A EA 029690 B1 EA029690 B1 EA 029690B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage form
release
oral dosage
pharmaceutical oral
riboflavin
Prior art date
Application number
EA201690149A
Other languages
English (en)
Russian (ru)
Other versions
EA201690149A1 (ru
Inventor
Манон Врандерик
Жан-Люк Ст-Онж
Микеле Галло
Эрик Жерве
Original Assignee
Дюшене Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA029690(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дюшене Инк. filed Critical Дюшене Инк.
Publication of EA201690149A1 publication Critical patent/EA201690149A1/ru
Publication of EA029690B1 publication Critical patent/EA029690B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
EA201690149A 2013-07-22 2014-03-13 Композиция для контроля тошноты и рвоты EA029690B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856971P 2013-07-22 2013-07-22
PCT/CA2014/050231 WO2015010194A1 (en) 2013-07-22 2014-03-13 Composition for the management of nausea and vomiting

Publications (2)

Publication Number Publication Date
EA201690149A1 EA201690149A1 (ru) 2016-06-30
EA029690B1 true EA029690B1 (ru) 2018-04-30

Family

ID=50877783

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690149A EA029690B1 (ru) 2013-07-22 2014-03-13 Композиция для контроля тошноты и рвоты

Country Status (28)

Country Link
US (3) US10028941B2 (enExample)
EP (1) EP3024466B1 (enExample)
JP (1) JP6379194B2 (enExample)
KR (1) KR102242391B1 (enExample)
CN (1) CN105492013B (enExample)
AR (1) AR097023A1 (enExample)
AU (1) AU2014295765B2 (enExample)
BR (1) BR112016001474A2 (enExample)
CA (1) CA2847022C (enExample)
CL (1) CL2016000154A1 (enExample)
CY (1) CY1120386T1 (enExample)
DK (1) DK3024466T3 (enExample)
EA (1) EA029690B1 (enExample)
ES (1) ES2670619T3 (enExample)
HU (1) HUE039131T2 (enExample)
IL (1) IL243638B (enExample)
MX (1) MX366760B (enExample)
MY (1) MY191347A (enExample)
NO (1) NO3086669T3 (enExample)
NZ (1) NZ716017A (enExample)
PL (1) PL3024466T3 (enExample)
PT (1) PT3024466T (enExample)
SA (1) SA516370443B1 (enExample)
SG (1) SG11201600122RA (enExample)
TW (2) TWI654977B (enExample)
UY (1) UY35674A (enExample)
WO (1) WO2015010194A1 (enExample)
ZA (1) ZA201600383B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565232A4 (en) * 2023-03-01 2026-07-29 Akums Drugs And Pharmaceuticals Ltd Stable tablet-in-tablet composition for nausea and vomiting during pregnancy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5914701B2 (ja) 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US10244873B2 (en) 2015-10-01 2019-04-02 Isee Store Innovations, Llc Adjustable product display system and method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017341A2 (en) * 2004-07-12 2006-02-16 Umd, Inc. Coated vaginal devices for vaginal delivery of therapeutically effective and/ or health-promoting agents

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6514481B1 (en) 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
DE60219607T2 (de) 2001-01-09 2007-12-27 Microchips, Inc., Bedford Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
AU2003303288B2 (en) 2002-08-16 2006-12-07 Microchips, Inc. Controlled release device and method
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
ATE424928T1 (de) 2004-09-01 2009-03-15 Microchips Inc Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
KR101190708B1 (ko) 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CN103037849A (zh) 2010-06-22 2013-04-10 安成国际药业股份有限公司 具有减少的食物效应的控释组合物
CN103402502A (zh) 2011-02-14 2013-11-20 宝洁公司 包衣中包含蜂蜜的膜包衣固体剂型
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP5914701B2 (ja) 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017341A2 (en) * 2004-07-12 2006-02-16 Umd, Inc. Coated vaginal devices for vaginal delivery of therapeutically effective and/ or health-promoting agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASHKENAZI-HOFFNUNG et al., Isr. Med. Assoc. J., 15(1), pp. 23-26. January 2013 (01-2013) "Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy" [ISSN: 1565-1088 (Print)] http://www.ima.org.il/FilesUpload/IMAJ/0/48/24198.pdf *
KOREN et al., Am. J. Obstet. Gynecol., 203(6). pp. 571.el-571.e7 December 2010 (12-2010) "Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: A randomized placebo controlled trial" [ISSN: 0002-9378 (Print); 1097-6868 (Electronic)] http://dx.doi.org/10.1016/j.ajog.2010.07.030 *
NULMAN et al. Can. J. Clin. Pharmacol.. 16(3). pp. e400-e406. September 2009 (09-2009) Epub 29 October 2009 (29-10-2009) "Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (diclectin®) and oral solutions of these drugs in healthy women of childbearing age." [ISSN: 1198-581X (Print)] http://www.jptcp.com/pubmed.php?articleId=218 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565232A4 (en) * 2023-03-01 2026-07-29 Akums Drugs And Pharmaceuticals Ltd Stable tablet-in-tablet composition for nausea and vomiting during pregnancy

Also Published As

Publication number Publication date
EP3024466A1 (en) 2016-06-01
CA2847022C (en) 2015-04-07
MY191347A (en) 2022-06-17
PT3024466T (pt) 2018-07-13
EA201690149A1 (ru) 2016-06-30
CL2016000154A1 (es) 2016-08-05
JP6379194B2 (ja) 2018-08-22
TW201720442A (zh) 2017-06-16
US20150025033A1 (en) 2015-01-22
KR102242391B1 (ko) 2021-04-21
HUE039131T2 (hu) 2018-12-28
MX2016000884A (es) 2016-05-05
EP3024466B1 (en) 2018-04-04
ES2670619T3 (es) 2018-05-31
NO3086669T3 (enExample) 2018-06-23
PL3024466T3 (pl) 2018-08-31
TW201513860A (zh) 2015-04-16
US10028941B2 (en) 2018-07-24
HK1218264A1 (en) 2017-02-10
SG11201600122RA (en) 2016-02-26
UY35674A (es) 2014-12-31
BR112016001474A2 (pt) 2020-04-14
JP2016527237A (ja) 2016-09-08
MX366760B (es) 2019-07-23
KR20160033201A (ko) 2016-03-25
DK3024466T3 (en) 2018-06-06
CN105492013B (zh) 2018-09-18
CN105492013A (zh) 2016-04-13
TWI589292B (zh) 2017-07-01
US20160143892A1 (en) 2016-05-26
NZ716017A (en) 2020-07-31
IL243638B (en) 2019-09-26
EP3024466A4 (en) 2017-03-29
WO2015010194A1 (en) 2015-01-29
AU2014295765B2 (en) 2019-02-14
CY1120386T1 (el) 2019-07-10
US9452181B2 (en) 2016-09-27
SA516370443B1 (ar) 2018-08-08
US9439920B2 (en) 2016-09-13
ZA201600383B (en) 2017-11-29
AR097023A1 (es) 2016-02-10
TWI654977B (zh) 2019-04-01
US20150025032A1 (en) 2015-01-22
AU2014295765A1 (en) 2016-02-04
CA2847022A1 (en) 2014-06-03
IL243638A0 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
US9937132B2 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2013123569A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
AU2014295765B2 (en) Composition for the management of nausea and vomiting
HK1218264B (en) Composition for the management of nausea and vomiting
HK1247571B (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
HK1247571A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof